The HbA1c and FBS levels improved in 63 (70.8%) and 59 (66.3%) patients, respectively.<h4>Conclusion</h4>Consultations incorporating the M2-PRIME were associated with clinically meaningful pre-post reductions in HbA1c and FBS levels among poorly controlled insulin-treated T2DM cases. The gene discussed is INS; the disease is type 2 diabetes mellitus.